P. Ravdin

发表

Cathepsin D by western blotting and immunohistochemistry: failure to confirm correlations with prognosis in node-negative breast cancer.

S. Fuqua, D. Allred, G. Clark, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Decision-making in early breast cancer: guidelines and decision tools.

P. Ravdin, M. Baum, 2002, European journal of cancer.

Doctor‐patient communication patterns in breast cancer adjuvant therapy discussions

N. Colabianchi, P. Ravdin, L. Siminoff, 2000, Health expectations : an international journal of public participation in health care and health policy.

Tamoxifen for early breast cancer: an overview of the randomised trials

Mike Clarke, Luc Bijnens, Michael Gnant, 1998, The Lancet.

Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer.

P. Ravdin, L. Siminoff, G. Davis, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial.

Robert B Livingston, Lois Shepherd, James N Ingle, 2010, The Lancet. Oncology.

A prognostic model that makes quantitative estimates of probability of relapse for breast cancer patients.

P M Ravdin, G M Clark, G. Clark, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Time-dependence of hazard ratios for prognostic factors in primary breast cancer

S. Hilsenbeck, C. Osborne, G. Clark, 2004, Breast Cancer Research and Treatment.

A demonstration that breast cancer recurrence can be predicted by Neural Network analysis

W. McGuire, M. Pandian, G. Clark, 2005, Breast Cancer Research and Treatment.

American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.

R. Bast, M. Somerfield, L. Norton, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features.

Robert Gray, Sunil Badve, Edith A Perez, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ki67 in breast cancer: prognostic and predictive potential.

K. Gelmon, P. Ravdin, R. Woods, 2010, The Lancet. Oncology.

Lateral motion of fluorescently labeled acetylcholine receptors in membranes of developing muscle fibers.

W. Webb, E. Elson, J. Schlessinger, 1976, Proceedings of the National Academy of Sciences of the United States of America.

70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.

L. V. van't Veer, A. Glas, R. Bernards, 2016, The New England journal of medicine.

American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.

R. Bast, M. Somerfield, L. Norton, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A practical application of neural network analysis for predicting outcome of individual breast cancer patients

G. Clark, P. Ravdin, 2005, Breast Cancer Research and Treatment.

The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine.

J. Ross, G. Hortobagyi, L. Pusztai, 2009, The oncologist.

Prospective Validation of a 21-Gene Expression Assay in Breast Cancer.

Virginia G Kaklamani, Soonmyung Paik, Ingrid A Mayer, 2015, The New England journal of medicine.

Accumulation of p53 protein as a possible predictor of response to adjuvant combination chemotherapy with cyclophosphamide, methotrexate, fluorouracil, and prednisone for breast cancer.

R. Gray, C. Osborne, N. Robert, 1995, Journal of the National Cancer Institute.

Gene Polymorphisms in Cyclophosphamide Metabolism Pathway, Treatment-Related Toxicity, and Disease-Free Survival in SWOG 8897 Clinical Trial for Breast Cancer

G. Hortobagyi, S. Martino, S. Yao, 2010, Clinical Cancer Research.

Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial

Marc Buyse, Stella Mook, Jan Bogaerts, 2006, Nature Clinical Practice Oncology.

Neural Network Analysis of DNA flow cytometry histograms.

P M Ravdin, J. J. Hough, G M Clark, 1993, Cytometry.

The decrease in breast-cancer incidence in 2003 in the United States.

Eric J Feuer, Kathleen A Cronin, Nadia Howlader, 2007, The New England journal of medicine.

Phase II trial of piroxantrone in metastatic breast cancer

S. Martino, J. Doroshow, P. Ravdin, 1994, Investigational New Drugs.

NCCN Task Force Report: Estrogen Receptor and Progesterone Receptor Testing in Breast Cancer by Immunohistochemistry.

Donald A Berry, D. Berry, A. Gown, 2009, Journal of the National Comprehensive Cancer Network : JNCCN.

Computer P rogram t o A ssist i n M aking D ecisions A bout Adjuvant T herapy f or W omen W ith E arly B reast C ancer

P. Ravdin, L. Siminoff, G. Davis, 2001 .

Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer.

B. Overmoyer, P. Ravdin, W. Urba, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

Terry L. Smith, R. Collins, L. Holmberg, 1998, Lancet.

Managing the risk of osteoporosis in women with a history of early breast cancer.

P. Ravdin, 2004, Oncology.

A method for making estimates of the benefit of the late use of letrozole in patients completing 5 years of tamoxifen.

P. Ravdin, G. Davis, 2004, Clinical breast cancer.

Choosing between Endocrine Therapy and Chemotherapy – or is there a Role for Combination Therapy?

J. Forbes, W. Gradishar, P. Ravdin, 2002, Breast Cancer Research and Treatment.

Aromatase inhibitors in adjuvant therapy: promise and uncertainty

P. Ravdin, 2004 .

Aromatase inhibitors for the endocrine adjuvant treatment of breast cancer

P. Ravdin, 2002, The Lancet.

Overview of randomized trials of systemic adjuvant therapy.

P. Ravdin, 2000, Cancer treatment and research.

Prognostic factors: Rationale and methods of analysis and integration

S. Hilsenbeck, C. Osborne, G. Clark, 2004, Breast Cancer Research and Treatment.

Should HER2 status be routinely measured for all breast cancer patients?

P. Ravdin, 1999, Seminars in oncology.

70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age.

A. Glas, C. Sotiriou, M. Delorenzi, 2021, The Lancet. Oncology.

Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials

E. Rutgers, E. Winer, J. Cuzick, 2015, The Lancet.

4–34 Treatment of Axillary Lymph Node–Negative, Estrogen Receptor–Negative Breast Cancer: Updated Findings From National Surgical Adjuvant Breast and Bowel Project Clinical Trials

P. Ravdin, 2006 .

Prediction of axillary lymph node status in breast cancer patients by use of prognostic indicators.

P M Ravdin, G M Clark, G. Clark, 1994, Journal of the National Cancer Institute.

S3 The changes in breast cancer incidence: A result of recent changes in hormone use by postmenopausal women?

P. Ravdin, 2009 .

Estrogen receptor (ER) and progesterone receptor (PgR), by ligand‐binding assay compared with ER, PgR and pS2, by immuno‐histochemistry in predicting response to tamoxifen in metastatic breast cancer: A Southwest Oncology Group study

S. Martino, R. Elledge, G. Clark, 2000, International journal of cancer.

Genome-wide DNA methylation profiling reveals parity-associated hypermethylation of FOXA1

Howard Wang, Yanfen Hu, Rong Li, 2014, Breast Cancer Research and Treatment.

Clinical Guidelines Annals of Internal Medicine Effects of Mammography Screening Under Different Screening

Marvin Zelen, Harry J de Koning, Eric J Feuer, 2022 .

A computer program to assist in making breast cancer adjuvant therapy decisions.

P. Ravdin, 1996, Seminars in oncology.

Sustained lower rates of breast cancer in the United States

B. Edwards, P. Ravdin, K. Cronin, 2009, Breast Cancer Research and Treatment.

Review of docetaxel (Taxotere), a highly active new agent for the treatment of metastatic breast cancer.

V. Valero, P. Ravdin, 1995, Seminars in oncology.

Do American oncologists know how to use prognostic variables for patients with newly diagnosed primary breast cancer?

P. Novotny, C. Loprinzi, P. Ravdin, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Case report: use of insulin-like growth factor-I gene expression to distinguish between breast and ovarian cancer.

D. Yee, P. Ravdin, J. Jackson, 1994, The American journal of the medical sciences.

A practical view of prognostic factors for staging, adjuvant treatment planning, and as baseline studies for possible future therapy.

P. Ravdin, 1994, Hematology/oncology clinics of North America.

Accuracy of the online prognostication tools PREDICT and Adjuvant! for early-stage breast cancer patients younger than 50 years.

R. Tollenaar, A. Stiggelbout, M. Schmidt, 2017, European journal of cancer.

Docetaxel versus paclitaxel in the adjuvant setting: Translating SABCS into clinical practice

P. Ravdin, 2006 .

Internalization of alpha-bungarotoxin on neurons induced by a neurotoxin that blocks neuronal acetylcholine sensitivity

P. Ravdin, D. K. Berg, R. Nitkin, 1981, The Journal of neuroscience : the official journal of the Society for Neuroscience.

Myeloperoxidase genotypes and enhanced efficacy of chemotherapy for early-stage breast cancer in SWOG-8897.

Ji-Yeob Choi, Robert B Livingston, Li Tang, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Manganese superoxide dismutase polymorphism, treatment-related toxicity and disease-free survival in SWOG 8897 clinical trial for breast cancer

G. Hortobagyi, S. Martino, S. Yao, 2010, Breast Cancer Research and Treatment.

Nerve extract induces increase and redistribution of acetylcholine receptors on cloned muscle cells.

M. Salpeter, P. Ravdin, D. Axelrod, 1978, Proceedings of the National Academy of Sciences of the United States of America.

Update of Recommendat ions for the Use of Tumor Markers in Breast and Colorecta l Cancer : Cl in ica l Pract ice Guidel ines of the American Socie ty of Cl in ica l Oncology *

R. Bast, M. Somerfield, S. Bates, 2001 .

A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer.

G. Hortobagyi, V. Valero, D. Booser, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Anthracycline resistance in breast cancer: clinical applications of current knowledge.

P. Ravdin, 1995, European journal of cancer.

Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials

Mike Clarke, Yasuo Ohashi, Michael Gnant, 2018, The Lancet. Oncology.

A Southwest Oncology Group Randomized Phase II Study of Doxorubicin and Paclitaxel as Frontline Chemotherapy for Women with Metastatic Breast Cancer

S. Martino, C. Geyer, G. Lyman, 2004, Breast Cancer Research and Treatment.

Treatment of patients resistant to anthracycline therapy

P. Ravdin, 1996, Anti-cancer drugs.

bcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group study.

C. Osborne, S. Martino, R. Elledge, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Failure of GM-CSF to permit dose-escalation in an every other week dose-intensive regimen for advanced breast cancer.

C. Osborne, P. Ravdin, M. Abeloff, 1994, Annals of Oncology.

Cardiac function following combination therapy with paclitaxel and doxorubicin: an analysis of 657 women with advanced breast cancer.

D. Amadori, G. Sledge, S. Arbuck, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Hormone replacement therapy and the increase in the incidence of invasive lobular cancer.

P. Ravdin, 2008, Breast disease.

hsp7O: Lack of Correlation with Response to Tamoxifen and Clinical Course of Disease in Estrogen Receptor-positive Metastatic Breast Cancer (A Southwest Oncology Group Study)’

S. Martino, R. Elledge, G. Clark, 2005 .

A computer based program to assist in adjuvant therapy decisions for individual breast cancer patients.

P. Ravdin, 1995, Bulletin du cancer.

Docetaxel (Taxotere) for the treatment of anthracycline-resistant breast cancer.

P. Ravdin, 1997, Seminars in oncology.

Preparation of a monoclonal antibody specific for the class I isotype of beta-tubulin: the beta isotypes of tubulin differ in their cellular distributions within human tissues.

P. Ravdin, R. Luduena, C. Walss, 1998, Cell motility and the cytoskeleton.

A phase I study of docetaxel and 5-fluorouracil in patients with advanced solid malignancies.

D. V. Von Hoff, T. Petit, P. Ravdin, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Estrogenic effects of phenolphthalein on human breast cancer cellsin vitro

P. Ravdin, V. Jordan, M. Beurden, 1987, Breast Cancer Research and Treatment.

How can prognostic and predictive factors in breast cancer be used in a practical way today?

P. Ravdin, 1998, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Prediction model for estimating the survival benefit of adjuvant radiotherapy for gallbladder cancer.

Dean F Sittig, Dean F. Sittig, Charles R. Thomas, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Reflections on the development of resistance during therapy for advanced breast cancer. Implications of high levels of activity of docetaxel in anthracycline-resistant breast cancer patients.

P. Ravdin, 1997, European journal of cancer.

Heat shock proteins hsp27 and hsp70: lack of correlation with response to tamoxifen and clinical course of disease in estrogen receptor-positive metastatic breast cancer (a Southwest Oncology Group Study).

C. Osborne, S. Martino, R. Elledge, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer.

L B Sheiner, A Riva, P M Ravdin, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Docetaxel in combination with fluorouracil: study design and preliminary results.

D. V. Von Hoff, P. Ravdin, H. Burris, 1997, Oncology.

Significant increased recurrence rates among breast cancer patients with HER2-positive, T1a,bN0M0 tumors.

D. Larsimont, M. Piccart, G. Hortobagyi, 2009 .

Prognosis and treatment decisions in patients with breast cancer without axillary node involvement

W. McGuire, D. Allred, P. Ravdin, 1992, Cancer.

An independent population-based validation of the adjuvant decision-aid for stage I-II breast cancer.

K. Gelmon, P. Ravdin, S. Chia, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Inhibition of neuronal acetylcholine sensitivity by α-toxins from Bungarus multicinctus venom

P. Ravdin, D. K. Berg, 1979 .

Inhibition of neuronal acetylcholine sensitivity by alpha-toxins from Bungarus multicinctus venom.

P. Ravdin, D. K. Berg, 1979, Proceedings of the National Academy of Sciences of the United States of America.

Control of acetylcholine receptor mobility and distribution in cultured muscle membranes. A fluorescence study.

P. Ravdin, D. Axelrod, T. Podleski, 1978, Biochimica et biophysica acta.

Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials

Bingshu E. Chen, D. Berry, P. Fasching, 2019, The Lancet.

Effect of submandibular gland removal on carcinogen induced rat mammary tumors.

P. Ravdin, S. Robinson, V. Jordan, 1987, European journal of cancer & clinical oncology.

High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller.

Funda Meric-Bernstam, Kristine R Broglio, Denis Larsimont, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer

P. Ravdin, 1999 .

Adjuvant Chemotherapy Guided by a 21‐Gene Expression Assay in Breast Cancer

Virginia G Kaklamani, Soonmyung Paik, Matthew P Goetz, 2018, The New England journal of medicine.

Population-based validation of the prognostic model ADJUVANT! for early breast cancer.

Karen A Gelmon, K. Gelmon, P. Ravdin, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study.

W. McGuire, P. Ravdin, C. Fabian, 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Survival analysis of censored data: Neural network analysis detection of complex interactions between variables

Michele De Laurentiis, Peter M. Ravdin, P. Ravdin, 2004, Breast Cancer Research and Treatment.

Prognostic factors in early breast carcinoma

P. Ravdin, E. Mansour, Peter M. Ravdin, 1994, Cancer.

The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers--a review.

P. Ravdin, G. Chamness, 1995, Gene.

Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women.

J. Manson, R. Prentice, L. Kuller, 2010, JAMA.

Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol INT-0102.

C. Osborne, S. Martino, P. Ravdin, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Fluorescent tetramethyl rhodamine derivatives of alpha-bungarotoxin: preparation, separation, and characterization.

P. Ravdin, D. Axelrod, Peter Ravdin, 1977, Analytical biochemistry.

Cloned myogenic cells during differentiation: membrane biochemistry and fine structural observations.

M. Salpeter, P. Ravdin, T. Podleski, 1979, Developmental biology.

Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial

S. Martino, R. Livingston, W. Barlow, 2009, The Lancet.

Poor-Prognosis Estrogen Receptor–Positive Breast Cancer Identified by Histopathologic Subclassification

I. Ellis, K. Byth, A. Green, 2008, Clinical Cancer Research.

Endocrine status of premenopausal node-positive breast cancer patients following adjuvant chemotherapy and long-term tamoxifen.

P. Ravdin, V. Jordan, D. Tormey, 1988, Cancer research.

Active immunization to luteinizing hormone releasing hormone to inhibit the induction of mammary tumors in the rat.

P. Ravdin, V. Jordan, 1988, Life sciences.

The EORTC 10041/BIG 03-04 MINDACT trial is feasible: results of the pilot phase.

E. Rutgers, J. Bogaerts, F. Cardoso, 2011, European journal of cancer.

Calibration and discriminatory accuracy of prognosis calculation for breast cancer with the online Adjuvant! program: a hospital-based retrospective cohort study.

S. Mook, M. Schmidt, E. Rutgers, 2009, The Lancet. Oncology.

Is Her2 of value in identifying patients who particularly benefit from anthracyclines during adjuvant therapy? A qualified yes.

P. Ravdin, 2001, Journal of the National Cancer Institute. Monographs.

Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer.

Virginia G Kaklamani, Soonmyung Paik, Matthew P Goetz, 2019, The New England journal of medicine.

Cancer and Leukemia Group B Pathology Committee guidelines for tissue microarray construction representing multicenter prospective clinical trial tissues.

D. Berry, F. Waldman, T. Nielsen, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Evaluation of cathepsin D as a prognostic factor in breast cancer

P. Ravdin, 1993, Breast cancer research and treatment.

Association Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer.

R. Jagsi, W. Woodward, G. Hortobagyi, 2020, JAMA oncology.

Standard Anthracycline Based Versus Docetaxel-Capecitabine in Early High Clinical and/or Genomic Risk Breast Cancer in the EORTC 10041/BIG 3-04 MINDACT Phase III Trial.

M. Piccart, E. Rutgers, S. Litière, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study.

S. Martino, R. Elledge, D. Allred, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer

A. Glas, R. Bernards, C. Sotiriou, 2016 .

Title : 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer

A. Glas, R. Bernards, C. Sotiriou, 2022 .

Correspondence re: Mills SE, Kempson RL, Fechner RE, et al.: Guardians of the wax ... and the patient. Mod Pathol 8:699, 1995.

V. Pinn, H. Anton-Culver, P. Ravdin, 1996, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

Survey of breast cancer patients concerning their knowledge and expectations of adjuvant therapy.

P. Ravdin, J. Harvey, P. Ravdin, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

NCCN Task Force Report: Bone Health and Cancer Care.

C. Shapiro, R. Theriault, D. Podoloff, 2006, Journal of the National Comprehensive Cancer Network : JNCCN.

Taxoids: effective agents in anthracycline-resistant breast cancer.

P. Ravdin, 1995, Seminars in oncology.

Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer.

P M Ravdin, J. Mortimer, G. Cook, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A technique for using neural network analysis to perform survival analysis of censored data.

M De Laurentiis, P M Ravdin, P. Ravdin, 1994, Cancer letters.

Special Issues Concerning Postmenopausal Hormone Replacement Therapy and Breast Cancer

P. Ravdin, 1994 .

Patterns of treatment for early stage breast cancers at the M. D. Anderson Cancer Center from 1997 to 2004

R. Theriault, Yu Shen, P. Ravdin, 2009, Cancer.

Breast cancer after use of estrogen plus progestin in postmenopausal women.

J. Manson, R. Prentice, L. Kuller, 2009, The New England journal of medicine.

Independent prognostic value of screen detection in invasive breast cancer.

S. Mook, M. Schmidt, E. Rutgers, 2011, Journal of the National Cancer Institute.

Epidemiology of GIST in the Era of Histology Codes—Letter

A. Lin, P. Ravdin, A. Hsing, 2015, Cancer Epidemiology, Biomarkers & Prevention.

NCCN Task Force Report: Adjuvant Therapy for Breast Cancer.

E. Winer, E. Perez, C. Hudis, 2006, Journal of the National Comprehensive Cancer Network : JNCCN.

Breast cancer trends: a marriage between clinical trial evidence and epidemiology.

D. Berry, P. Ravdin, 2007, Journal of the National Cancer Institute.

Decreased Use of Adjuvant Breast Cancer Therapy in a Randomized Controlled Trial of a Decision Aid with Individualized Risk Information

P. Ravdin, L. Siminoff, P. Peele, 2005, Medical decision making : an international journal of the Society for Medical Decision Making.

Treatment decisions in axillary node-negative breast cancer patients.

P M Ravdin, G M Clark, D. Allred, 1992, Journal of the National Cancer Institute. Monographs.

Radiation therapy and survival in breast cancer patients with 10 or more positive axillary lymph nodes treated with mastectomy.

R. Elledge, G. Clark, P. Ravdin, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Nitric Oxide Synthase Variants and Disease-Free Survival among Treated and Untreated Breast Cancer Patients in a Southwest Oncology Group Clinical Trial

S. Martino, R. Livingston, W. Barlow, 2009, Clinical Cancer Research.

1997 update of recommendations for the use of tumor markers in breast and colorectal cancer. Adopted on November 7, 1997 by the American Society of Clinical Oncology.

Thomas J. Smith, Robert C. Bast, Daniel F. Hayes, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

JNCCN NCCN Task Force Report : Adjuvant Therapy for Breast Cancer — Clarification and Expansion of NCCN Clinical Practice Guidelines

E. Winer, E. Perez, C. Hudis, 2006 .

The Lack, Need, and Opportunities for Decision-Making and Informational Tools to Educate Primary-Care Physicians and Women about Breast Cancer Chemoprevention

P. Ravdin, Peter M Ravdin, 2010, Cancer Prevention Research.

A decision aid to assist in adjuvant therapy choices for breast cancer

P. Ravdin, L. Siminoff, N. Gordon, 2006, Psycho-oncology.

Defining the role of aromatase inhibitors in the adjuvant endocrine treatment of early breast cancer

J. Cuzick, J. Forbes, A. Buzdar, 2006, Current medical research and opinion.

As the Median Size of Invasive Breast Cancers at Time of Diagnosis Continues to Fall, How Does the Oncologist Guard Against Over-Treatment?

P. Ravdin, 2006 .

Decision-making for patients with resectable breast cancer: individualized decisions for and by patients and their physicians.

C. Loprinzi, P. Ravdin, 2003, Journal of the National Comprehensive Cancer Network : JNCCN.

Communicating Risks of Adjuvant Chemotherapy for Breast Cancer: Getting Beyond the Laundry List.

Elisa F. Long, P. Ganz, P. Ravdin, 2019, Journal of oncology practice.

Prognosis of patients with resected non-small cell lung cancer: impact of clinical and pathologic variables.

P. Ravdin, G. Davis, 2006, Lung cancer.

Germline Genetic Variants in GATA3 and Breast Cancer Treatment Outcomes in SWOG S8897 Trial and the Pathways Study.

G. Hortobagyi, Qianqian Zhu, Song Liu, 2019, Clinical breast cancer.

A phase I clinical and pharmacokinetic trial of hepsulfam.

J. Koeller, D. V. Von Hoff, P. Ravdin, 1991, Cancer research.

Lack of prognostic value of cathepsin D levels for predicting short term outcomes of breast cancer patients.

G. Clark, P. Ravdin, S. Hilsenbeck, 1997, Cancer letters.

A Phase I Clinical and Pharmacokinetic Trial of Hepsulfam 1

P. Ravdin, D. V. Hoff, T. Brown, 2006 .

The international experience with docetaxel in the treatment of breast cancer.

P. Ravdin, 1997, Oncology.

The 21-Gene Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer Treated on SWOG S8814

R. Jagsi, W. Woodward, G. Hortobagyi, 2016 .

670 Phase III comparison of docetaxel (D)and pacilitaxel (P) in patients with metastatic breast cancer (MBC)

B. Overmoyer, P. Ravdin, W. Urba, 2003 .

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Y Wang, Mike Clarke, Donald A. Berry, 2005, The Lancet.

Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial

E. Rutgers, S. Loi, M. Buyse, 2006, Nature Clinical Practice Oncology.

Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers.

R. Bast, L. Norton, C. Desch, 1996, Journal of the National Cancer Institute.

2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology.

R. Bast, M. Somerfield, S. Bates, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms.

D. Berry, E. Feuer, S. Plevritis, 2009, Annals of internal medicine.

Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials

S. Steinberg, E. Rutgers, E. Winer, 2018, The Lancet. Oncology.

American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer.

R. Bast, M. Somerfield, L. Norton, 2007, Journal of oncology practice.

Case report: use of insulin-like growth factor-I gene expression to distinguish between breast and ovarian cancer.

D. Yee, D. V. Von Hoff, P. Ravdin, 1994, The American journal of the medical sciences.

Abstract GS4-07: Race, ethnicity and clinical outcomes in hormone receptor-positive, HER2-negative, node-negative breast cancer: results from the TAILORx trial

R. Gray, H. Gómez, S. Paik, 2019, General Session Abstracts.

American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.

R. Bast, M. Somerfield, L. Norton, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prospective Validation of a 21-Gene Expression Assay in Breast Cancer.

J. Olson, M. Ellis, R. Gray, 2015, The New England journal of medicine.

Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials

E. Rutgers, E. Winer, J. Cuzick, 2015, The Lancet.

Gene Polymorphisms in Cyclophosphamide Metabolism Pathway, Treatment-Related Toxicity, and Disease-Free Survival in SWOG 8897 Clinical Trial for Breast Cancer

G. Hortobagyi, S. Martino, S. Yao, 2010, Clinical Cancer Research.

Breast cancer after use of estrogen plus progestin in postmenopausal women.

J. Manson, R. Prentice, L. Kuller, 2009, The New England journal of medicine.

Prediction of 10-Year Chemotherapy Benefit and Breast Cancer-Specific Survival by the 21-Gene Recurrence Score (RS) Assay in Node-Positive, ER-Positive Breast Cancer – An Update of SWOG-8814 (INT0100).

E. Winer, E. Perez, G. Hortobagyi, 2009 .